245 related articles for article (PubMed ID: 2826591)
1. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
2. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection.
Weinberg A; Basham TY; Merigan TC
J Immunol; 1986 Nov; 137(10):3310-7. PubMed ID: 3021853
[TBL] [Abstract][Full Text] [Related]
3. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
4. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
6. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
7. Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.
Weinberg A; Konrad M; Merigan TC
J Virol; 1987 Jul; 61(7):2120-7. PubMed ID: 3035213
[TBL] [Abstract][Full Text] [Related]
8. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
9. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
[TBL] [Abstract][Full Text] [Related]
10. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy.
Bernstein DI; Harrison CJ; Jenski LJ; Myers MG; Stanberry LR
J Immunol; 1991 May; 146(10):3571-7. PubMed ID: 1851194
[TBL] [Abstract][Full Text] [Related]
11. [Herpes simplex virus vaccine studies: from past to present].
Us D
Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
13. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.
Strasser JE; Arnold RL; Pachuk C; Higgins TJ; Bernstein DI
J Infect Dis; 2000 Nov; 182(5):1304-10. PubMed ID: 11023454
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
Nesburn AB; Burke RL; Ghiasi H; Slanina SM; Wechsler SL
Virology; 1998 Dec; 252(1):200-9. PubMed ID: 9875329
[TBL] [Abstract][Full Text] [Related]
17. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
19. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.
Scriba M
Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688
[TBL] [Abstract][Full Text] [Related]
20. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
Martin S; Rouse BT
J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
